Giant cell arteritis and cardiovascular disease in older adults

Heart

Volumn 91, Issue 3, 2005, Pages 324-328

  Ray, Joel G ^a   Mamdani, M M ^b,d   Geerts, W H ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANEURYSM; AORTA DISSECTION; ARTERY DISEASE; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; GIANT CELL ARTERITIS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; STROKE; AORTA ANEURYSM; AORTA DISEASE; CEREBROVASCULAR ACCIDENT; PERIPHERAL VASCULAR DISEASE; TEMPORAL ARTERITIS;

CORTICOSTEROID;

ADRENAL CORTEX HORMONES; AGED; AORTIC ANEURYSM; AORTIC DISEASES; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; FEMALE; HUMANS; MALE; OSTEOARTHRITIS; PERIPHERAL VASCULAR DISEASES; RETROSPECTIVE STUDIES; RISK FACTORS; TEMPORAL ARTERITIS;

EID: 14244265859     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.037481     Document Type: Article

References (40)

1. Mohan N, Kerr G. Spectrum of giant cell vasculitis. Curr Rheumatol Rep 2000;2:390-5.
2. Freddo T, Price M, Kase C, et al. Myocardial infarction and coronary artery involvement in giant cell arteritis. Optom Vis Sci 1999;76:14-8.
3. Nesher G. Neurologic manifestations of giant cell arteritis. Clin Exp Rheumatol 2000;18:S24-6.
4. Evens JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med 1995;122:502-7.
5. Le Hello C, Levesque H, Jeanton M, et al. Lower limb giant cell arteritis and temporal arteritis: followup of 8 cases. J Rheumatol 2001;28:1407-12.
6. Wagner AD, Gerard HC, Fresemann T, et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells. Arthritis Rheum 2000;43:1543-51.
7. Duhaut P, Berruyer M, Pinede L, et al. Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter case-control study. Groupe de Recherche sur l'Arterite a Cellules Geantes. Arthritis Rheum 1998;41:701-9.
8. Weyand CM, Goronzy JJ. Pathogenic mechanisms in giant cell arteritis. Cleve Clin J Med 2002;69(suppl 2):SII28-32.
9. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002;288:2724-31.
10. Lindholt JS, Ashton HA, Scott RA. Indicators of infection with Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysms. J Vasc Surg 2001;34:212-5.
11. Elkind MS, Lin IF, Grayston JT, et al. Chlamydia pneumoniae and the risk of first ischemic stroke: the Northern Manhattan stroke study. Stroke 2000;31:1521-5.
12. Tuhrim S, Rand JH, Wu XX, et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999;30:1561-5.
13. Puisieux F, de Groote P, Masy E, et al. Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease. Am J Med 2000;109:635-41.
14. Van Der Meer IM, De Maat MP, Hak AE, et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam study. Stroke 2002;33:2750-5.
15. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
16. Machado EB, Gabriel SE, Beard CM, et al. A population-based case-control study of temporal arteritis: evidence for an association between temporal arteritis and degenerative vascular disease? Int J Epidemiol 1989;18:836-41.
17. Hachulla E, Boivin V, Pasturel-Michon U, et al. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol 2001;19:171-6.
18. Singh G, Miller JD, Lee FH, et al. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the third national health and nutrition examination survey. Am J Manag Care 2002;8(15 suppl):S383-91.
19. Watson DJ, Rnodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK general practice research database. J Rheumatol 2003;30:1196-202.
20. Kobayashi S, Yano T, Matsumoto Y, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 2003;49:594-8.
21. Iezzoni LI, Foley SM, Daley J, et al. Comorbidities, complications, and coding bias: does the number of diagnosis codes matter in predicting in-hospital mortality? JAMA 1992;267:2197-203.
22. Brenner H, Savitz DA, Gefeller O. The effects of joint misclassification of exposure and disease on epidemiologic measures of association. J Clin Epidemiol 1993;46:1195-202.
23. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J 2002;144:290-6.
24. Humphries KH, Rankin JM, Carere RG, et al. Co-morbidity data in outcomes research: are clinical data derived from administrative databases a reliable alternative to chart review? J Clin Epidemiol 2000;53:343-9.
25. Bisgard C, Sloth H, Keiding N, et al. Excess mortality in giant cell arteritis. J Intern Med 1991;230:119-23.
26. Schaufelberger C, Bengtsson BA, Andersson R. Epidemiology and mortality in 220 patients with polymyalgia rheumatica. Br J Rheumatol 1995;34:261-4.
27. Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M, et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999;26:1326-32.
28. Gran JT, Myklebust G, Wilsgaard T, et al. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology 2001;40:1238-42.
29. Uddhammar A, Eriksson AL, Nystrom L, et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002;29:737-42.
30. Lie JT. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Semin Arthritis Rheum 1995;24:422-31.
31. Gonzalez-Alegre P, Ruiz-Lopez AD, Abarca-Costalago M, et al. Increment of the platelet count in temporal arteritis: response to therapy and ischemic complications. Eur Neurol 2001;45:43-5.
32. Liozon E, Venot J, Liozon F, et al. [Inflammation protein in Horton's disease: prospective study of 25 patients]. Ann Med Interne (Paris) 1990;141:319-24.
33. Folsom AR. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 2001;86:366-73.
34. Duhaut P, Pinede L, Demolombe-Rague S, et al. Giant cell arteritis and cardiovascular risk factors: a multicenter, prospective case-control study. Groupe de Recherche sur l'Arterite a Cellules Geantes. Arthritis Rheum 1998;41:1960-5.
35. Emilie D, Liozon E, Crevon MC, et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum Immunol 1994;39:17-24.
36. Voskuyl AE, Zwinderman AH, Westedt ML, et al. The mortality of rheumatoid vasculitis compared with rheumatoid arthritis. Arthritis Rheum 1996;39:266-71.
37. Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002;4:R5.
38. Gabriel SE. The sensitivity and specificity of computerized databases for the diagnosis of rheumatoid arthritis. Arthritis Rheum 1994;37:821-3.
39. Weyand CM, Kaiser M, Yang H, et al. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002;46:457-66.
40. Ansell BJ, Watson KE, Weiss RE, et al. hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels. A clinical investigation. Heart Dis 2003;5:2-7.